According to the company, full enrollment anticipated by first week of September. The phase 2 trial is designed as potential registration trial with pre-specified primary efficacy endpoints covering both a sign and symptom of DED.
We asked, "What research at ASRS 2023 do you find exciting or interesting?" Here's what Paul Hahn, MD, PhD, Kerrie Brady, BPharm, MBA, MS, and Michael Singer, MD had to say!
According to the Keck School of Medicine of USC, the $12.4 million from the California Institute for Regenerative Medicine is the latest round of support for USC researcher Mark Humayun and a milestone in the development of a stem cell patch to treat advanced dry age-related macular degeneration.
According to Outlook Therapeutics, it is working with the FDA to address the agency’s issues.
According to the company, it is anticipating cost savings of up to $300 million through 2024, which includes an estimated 25% reduction in current workforce and a reduction in external expenses.
ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.
More than 135 patients have been recruited in 4 months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204 ophthalmic solution as an adjunct to standard-of-care surgery.
Amber Bio is developing a first-of-its-kind RNA writing platform using multi-kilobase edits to reach previously undruggable patient populations.
The research by Scott N J Watamaniuk, PhD, has potential implications for patients diagnosed with strabismus.
Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.
The study, conducted by the National Eye Institute and University of Freiberg, Germany, sheds light on nerve function in the brain and retina.
This intellectual property protects Kiora's pipeline by covering multiple small molecule analogs, delivery methods, and several inflammatory-related therapeutic applications, including posterior non-infectious uveitis, extending market exclusivity for approved indications in the United States and Europe.
A team of researchers have successfully transplanted human microglia into a mouse retina to create a model for studying eye disease treatments, such as diabetic retinopathy, glaucoma and age-related macular degeneration.
According to researchers from University of Michigan and Duke University, children with Medicaid or other public insurance are far less likely than those with private insurance to have had a vision check in the last year at a primary care office.
Clinicians' expertise can help assess inconclusive findings about the benefits of blue-light filtering glasses. This enables them to offer informed guidance to patients concerned about eye strain and sleep quality.
The company noted that its Phase Ib dose-escalation clinical trial will evaluate safety, tolerability and efficacy of VG901 in patients with RP due to biallelic CNGA1 mutations.
Cultivated autologous limbal epithelial cells (CALEC) procedure shown to be safe and feasible with early positive results of restored cornea surfaces or vision gains in four patients with severe chemical burns.
According to the company, the primary endpoint for the NEXPEDE-1 study of lufepirsen ophthalmic gel will be complete corneal healing as determined by corneal fluorescein staining.
According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
An area that attracts tourists and Christian pilgrims from around the world, has been found to contain microsporidium, which can cause corneal infections.
According to the company, the MAA submission is based on data from the GATHER1 and GATHER2 Phase III clinical trials.
APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery.
Carl Regillo, MD, FACS, FASRS, spoke with our team following the annual ASRS meeting in Seattle, Washington to share insights from his presentation titled, "Modulation of Macrophages and Complement Dysfunction in Non-exudative AMD utilizing novel, sialic-acid coated nanoparticles." Aviceda Therapeutics is unlocking the proteogenomic code of AMD to target proteins and pathways linked to macular degeneration.
A team of researchers from the Netherlands Institute for Neuroscience, one of the causes is the spontaneous back-and-forth movement of the eye is pendular nystagmus. The researchers have demonstrated that the nucleus of the optic tract might be the source of the problem.
Theodore Leng, MD, sat down with David Hutton of Ophthalmology Times®, to discuss his ASRS presentation on how the real-world use of faricimab.
A team of researchers at Anglia Ruskin University are harnessing nanotechnology to help tackle a common cause of sight loss.
According to Orbis International, the technology proves to be a practical solution in low-resource communities for tackling the leading cause of vision loss among working-age adults.
According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.
An industrial engineer and entrepreneur, George Glady was a founder of Euclid Systems Corp. and developed the concept of the Ortho-K contact lenses.
According to Johns Hopkins Medicine, the gift brings T. Boone Pickens’ total donations to Wilmer to more than $28 million.
.png "Optometry Times"){kind=logo}
